Roche won the FDA's blessing to market a hemoglobin-based diabetes diagnostic, the latest advance in testing for the disease and the first assay of its kind approved in the U.S.
Pee on a stick, and then learn whether you have prostate cancer. That's the gist of a new, inexpensive test UC Irvine researchers have developed that would use urine instead of blood to screen for prostate cancer.
Doctors may be able to predict the likelihood of postpartum depression, Johns Hopkins researchers believe, by using a blood test that screens for two mutated genes. They studied mice and 52 pregnant women to identify the epigenetic biomarkers in question.
Interleukin Genetics just got a $12 million shot in the arm, a private placement funding that will be crucial to its survival as a developer of genetic tests for chronic conditions.
Fresh off the launch its gene-expression cancer diagnostic, Seattle's NanoString is plotting an IPO worth up to $86.3 million, the company disclosed Monday.
Quest Diagnostics is on a buying spree to grow its testing business, and now the company has signed a deal to buy the toxicology and clinical laboratory segment of health insurance giant Humana.
Roche may be trying to unload its blood glucose meter business, reflecting continued challenges over reimbursement, and a contrast from the far better success the company has enjoyed with diagnostics development.
NinePoint Medical, a 2012 Fierce 15 winner, has launched its NvisionVLE imaging system in the U.S., all part of the company's plan to get profitable and expand its technology.
Hip and knee implant makers, take note: Researchers have come up with a blood diagnostic test that detects allergies to nickel, a metal commonly used in those products.
Vermillion said it has raised a net of just under $12 million through a previously announced private placement. The Texas-based molecular diagnostics company also issued warrants that could boost that number another $18.3 million if and when the warrants are exercised.